SAO PAULO, Feb 7 (Reuters) - Brazilian healthcare company Hapvida said on Monday the acquisition of Notre Dame Intermedica is likely to add 1.38 billion reais ($259 million) to its earnings before interest, taxes, depreciation and amortization by 2024.

Revenue is expected to grow by 800 million reais, with likely cost savings of 580 million reais, according to a securities filing.

The integration should cost around 100-150 million reais by 2024, the company said.

Shares of both companies fell by more than 5% at midday, making them the worst performers on Brazil's Bovespa stock index , which was down 0.1%.

Analysts at Itau BBA attributed the sell-off to "synergies in the top line, which historically brings more uncertainty and higher risk, being the biggest chunk of the announced value."

Greater cost savings synergies were expected, they added in a research note.

"Given that even the most conservative expectation for synergies seems not to be fully priced in at the trading price, we see the reaction as exaggerated at this point."

Hapvida offered to buy rival Intermedica for 49 billion reais ($9.20 billion) in January 2021. The all-share deal, which is expected to close this month, will create the country's largest hospital chain.

($1 = 5.3253 reais) (Reporting by Gabriel Araujo and Peter Frontini; editing by Barbara Lewis and Richard Chang)